Symbols

MRKR

Marker Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MRKR

Marker Therapeutics, Inc.

A clinical-stage immuno-oncology company that develops next-generation T cell-based immunotherapies for hematological malignancies and solid tumor indications

Industry

Biological Technology

Established Date

Listing Date

11/08/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.markertherapeutics.com

Security Type

Common stock

Office address

9350 Kirby Drive, Suite 300, Houston, Texas 77054

Business

Introduction

Marker Therapeutics, Inc., is a clinical-stage immuno-oncology company specializing in the development of next-generation T-cell immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of unengineered tumor-specific T cells, which recognize tumor-associated antigens (i.e., tumor targets) and kill tumor cells expressing these targets. Once transfused into the patient, this group of T cells attacks multiple tumor targets and acts to activate the patient's immune system to generate broad-spectrum anti-tumor activity. Since Marker does not genetically engineer its T cells, its products are (i) less expensive, easier to manufacture, (ii) significantly less toxic, and (iii) associated with meaningful clinical benefits compared to current CAR-T and TCR-based engineering methods. Therefore, Marker believes that its T-cell therapy portfolio has a compelling therapeutic product profile compared to current genetically modified CAR-T and TCR-based therapies.

Company Financials

EPS

MRKR has released its 2025 Q3 earnings. EPS was reported at -0.12, versus the expected -0.21, beating expectations. The chart below visualizes how MRKR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MRKR has released its 2025 Q3 earnings report, with revenue of 1.23M, reflecting a YoY change of -35.99%, and net profit of -2.00M, showing a YoY change of 13.41%. The Sankey diagram below clearly presents MRKR's revenue sources and cost distribution.